{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-215939","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.103002+00:00","generated_at":"2026-05-31T05:59:45.616314+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Ionis proposes public offering of common stock; no size or price disclosed","bullets":["Filed preliminary prospectus supplement on Sep 9, 2024 for a registered underwritten public offering of common stock.","No specific number of shares, price range, or use of proceeds disclosed; offering subject to market conditions.","Business update in supplement notes five marketed drugs, nine Phase 3 programs, and key milestones like olezarsen PDUFA Dec 19, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-215939","json":"https://secwatch.observer/filing/0001193125-24-215939.json","markdown":"https://secwatch.observer/filing/0001193125-24-215939.md","text":"https://secwatch.observer/filing/0001193125-24-215939.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000119312524215939/0001193125-24-215939-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000119312524215939/d881331d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:59:45.616314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}